Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate Pharmaceutical Investing
U.S. FDA Accepts for Review the Biologics License Application for Pfizer's Investigational Pentavalent Meningococcal Vaccine Candidate in Adolescents Pharmaceutical Investing
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics Pharmaceutical Investing
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Sunlenca® Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV Pharmaceutical Investing
First tazarotene lotion treatment for acne vulgaris, ARAZLO , now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans Pharmaceutical Investing
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer Pharmaceutical Investing
Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group Pharmaceutical Investing
